Contribution of infection and vaccination to population-level seroprevalence through two COVID waves in Tamil Nadu, India

• Published in: Scientific reports 2024-01, Vol.14 (1), p.2091-2091, Article 2091
• Main Authors: Selvavinayagam, T. S., Somasundaram, Anavarathan, Selvam, Jerard Maria, Sampath, P., Vijayalakshmi, V., Kumar, C. Ajith Brabhu, Subramaniam, Sudharshini, Kumarasamy, Parthipan, Raju, S., Avudaiselvi, R., Prakash, V., Yogananth, N., Subramanian, Gurunathan, Roshini, A., Dhiliban, D. N., Imad, Sofia, Tandel, Vaidehi, Parasa, Rajeswari, Sachdeva, Stuti, Ramachandran, Sabareesh, Malani, Anup
• Format: Article
• Language: English
• Subjects: 631/250/255; 692/499; 692/699/255/2514; Antibodies; COVID-19 vaccines; Humanities and Social Sciences; Immunization; Infections; multidisciplinary; Rural areas; Science; Science (multidisciplinary); Serological surveys; Serology; Severe acute respiratory syndrome coronavirus 2; Urban areas; Vaccination
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-50338-3

This study employs repeated, large panels of serological surveys to document rapid and substantial waning of SARS-CoV-2 antibodies at the population level and to calculate the extent to which infection and vaccination separately contribute to seroprevalence estimates. Four rounds of serological surveys were conducted, spanning two COVID waves (October 2020 and April–May 2021), in Tamil Nadu (population 72 million) state in India. Each round included representative populations in each district of the state, totaling ≥ 20,000 persons per round. State-level seroprevalence was 31.5% in round 1 (October–November 2020), after India’s first COVID wave. Seroprevalence fell to 22.9% in round 2 (April 2021), a roughly one-third decline in 6 months, consistent with dramatic waning of SARS-Cov-2 antibodies from natural infection. Seroprevalence rose to 67.1% by round 3 (June–July 2021), with infections from the Delta-variant induced second COVID wave accounting for 74% of the increase. Seroprevalence rose to 93.1% by round 4 (December 2021–January 2022), with vaccinations accounting for 63% of the increase. Antibodies also appear to wane after vaccination. Seroprevalence in urban areas was higher than in rural areas, but the gap shrunk over time (35.7 v. 25.7% in round 1, 89.8% v. 91.4% in round 4) as the epidemic spread even in low-density rural areas.